Physician profile
Gregory D Blackmon
NPI 1609898865
$4,327.85
in general payments reported to CMS, 2019-2025
26 companies · $377 in 2025
The $377 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $568 · 2021: $593 · 2022: $751 · 2023: $691 · 2024: $391 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $669.47 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Tris Pharma INC | $594.02 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $454.71 | 2019-2024 | Jornay Pm |
| Kaleo, INC. | $425.74 | 2019-2023 | Auvi-Q |
| Sobi, INC | $364.96 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $335.64 | 2021-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $185.65 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $176.66 | 2019-2022 | |
| Adlon Therapeutics L.P. | $148.27 | 2019-2021 | |
| Sanofi Pasteur INC. | $143.37 | 2019-2025 | |
| Pfizer INC. | $139.67 | 2019-2025 | |
| Neos Therapeutics, LP | $134.85 | 2019-2024 | Cotempla Xr-Odt |
| Seqirus USA INC | $121.77 | 2022-2023 | Flucelvax Quadrivalent |
| Collegium Pharmaceutical, INC. | $87.25 | 2025 | Jornay Pm |
| Neurelis, INC. | $75.00 | 2022-2025 | Valtoco |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $61.18 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $37.49 | 2019 | |
| Hologic Sales and Service, LLC | $27.75 | 2019 | |
| Shire North American Group INC | $26.30 | 2019 | |
| Corium, LLC | $23.78 | 2022 | |
| Phadia US INC. | $22.69 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.83 | 2023 | Flumist Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $15.31 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.37 | 2020 | |
| Kyowa Kirin, INC. | $13.08 | 2023 | Crysvita |
| Novartis Pharmaceuticals Corporation | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Blackmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.